Medicus Pharma LTD. (MDCX) — SEC Filings
Latest SEC filings for Medicus Pharma LTD.. Recent 424B3 filing on Apr 23, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.
View Medicus Pharma LTD. on SEC EDGAR
Overview
Medicus Pharma LTD. (MDCX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 424B3 filed on Apr 23, 2026: Medicus Pharma Ltd. filed a 424B3 prospectus on April 23, 2026, detailing information about its securities. The filing, with SEC Accession No. 0001062993-26-002127, provides essential disclosures for potential investors regarding the company's offerings. The company's mailing and business address is
Sentiment Summary
Across 7 filings, the sentiment breakdown is: 7 neutral. The dominant filing sentiment for Medicus Pharma LTD. is neutral.
Filing Type Overview
Medicus Pharma LTD. (MDCX) has filed 5 4, 2 424B3 with the SEC between Mar 2026 to Apr 2026.
Recent Filings (7)
-
Medicus Pharma Ltd. Files 424B3 Prospectus
— 424B3 · Apr 23, 2026 Risk: medium
Medicus Pharma Ltd. filed a 424B3 prospectus on April 23, 2026, detailing information about its securities. The filing, with SEC Accession No. 0001062993-26-002 -
Medicus Pharma Ltd. Director Reports Ownership Change
— 4 · Apr 1, 2026 Risk: low
On March 30, 2026, Andrew Alasdair Smith, a director at Medicus Pharma Ltd., reported a change in beneficial ownership of securities. The filing details transac -
Medicus Pharma Ltd. Insider Ownership Change Reported
— 4 · Apr 1, 2026 Risk: low
On March 30, 2026, Patrick J. Mahafty, a reporting person associated with Medicus Pharma Ltd., reported a change in beneficial ownership of securities. The fili - 4 Filing — 4 · Apr 1, 2026
-
Medicus Pharma Ltd. Insider Ownership Update
— 4 · Apr 1, 2026 Risk: low
On March 30, 2026, Raza Bokhari, a reporting person associated with Medicus Pharma Ltd., reported a change in beneficial ownership of securities. The filing det - 4 Filing — 4 · Apr 1, 2026
-
Medicus Pharma Files 424B3 Prospectus Update
— 424B3 · Mar 25, 2026
Medicus Pharma Ltd. filed a 424B3 prospectus on March 25, 2026, which is a standard update to a previous registration statement (File No. 333-290585). This fili
Risk Profile
Risk Assessment: Of MDCX's 4 recent filings, 0 were flagged as high-risk, 1 as medium-risk, and 3 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Andrew Alasdair Smith
- 0001309614
- Patrick J. Mahafty
- Raza Bokhari
Top Tags
ownership-change (3) · prospectus (2) · insider-transaction (2) · securities-offering (1) · filing (1) · insider-filing (1) · regulatory-update (1) · capital-raise-prep (1)
Key Numbers
- Form Type: 424B3 — Indicates a prospectus supplement filing
- Filing Date: 2026-04-23 — Date the prospectus was filed with the SEC
Frequently Asked Questions
What are the latest SEC filings for Medicus Pharma LTD. (MDCX)?
Medicus Pharma LTD. has 7 recent SEC filings from Mar 2026 to Apr 2026, including 5 4, 2 424B3. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MDCX filings?
Across 7 filings, the sentiment breakdown is: 7 neutral. The dominant sentiment is neutral.
Where can I find Medicus Pharma LTD. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Medicus Pharma LTD. (MDCX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Medicus Pharma LTD.?
Financial highlights for Medicus Pharma LTD. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for MDCX?
Investment thesis data for MDCX will be available once enriched filings are processed.
Who are the key executives at Medicus Pharma LTD.?
Key executives identified across Medicus Pharma LTD.'s filings include Andrew Alasdair Smith, 0001309614, Patrick J. Mahafty, Raza Bokhari.
What are the main risk factors for Medicus Pharma LTD. stock?
Of MDCX's 4 assessed filings, 0 were flagged high-risk, 1 medium-risk, and 3 low-risk.
What are recent predictions and forward guidance from Medicus Pharma LTD.?
Forward guidance and predictions for Medicus Pharma LTD. are extracted from SEC filings as they are enriched.